Literature DB >> 34148084

Laparoscopic lavage for perforated diverticulitis in the LapLav study: population-based registry study.

A Samuelsson1,2,3, D Bock3, M Prytz1,2, M Block3,4, C Ehrencrona3, A Wedin3,4, M Ahlstedt3, E Angenete3,4, E Haglind3,4.   

Abstract

BACKGROUND: The standard treatment for Hinchey III perforated diverticulitis with peritonitis was resection with or without a stoma, but recent trials have shown that laparoscopic lavage is a reasonable alternative. This registry-based Swedish study investigated results at a national level to assess safety in real-world scenarios.
METHODS: Patients in Sweden who underwent emergency surgery for perforated diverticulitis between 2016 and 2018 were studied. Inverse probability weighting by propensity score was used to adjust for confounding factors.
RESULTS: A total of 499 patients were included in this study. Laparoscopic lavage was associated with a significantly lower 90-day Comprehensive Complication Index (20.9 versus 32.0; odds ratio 0.77, 95 per cent compatibility interval (c.i.) 0.61 to 0.97) and overall duration of hospital stay (9 versus 15 days; ratio of means 0.84, 95 per cent c.i. 0.74 to 0.96) compared with resection. Patients had 82 (95 per cent c.i. 39 to 140) per cent more readmissions following lavage than resection (27.2 versus 21.0 per cent), but similar reoperation rates. More co-morbidity was noted among patients who underwent resection than those who had laparoscopic lavage.
CONCLUSION: Laparoscopic lavage is safe in routine care beyond trial evaluations.
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2021        PMID: 34148084     DOI: 10.1093/bjs/znab211

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  1 in total

1.  Laparoscopic peritoneal lavage versus sigmoidectomy for perforated diverticulitis with purulent peritonitis: three-year follow-up of the randomised LOLA trial.

Authors:  Vincent T Hoek; Pim P Edomskis; Pieter W Stark; Daniel P V Lambrichts; Werner A Draaisma; Esther C J Consten; Johan F Lange; Willem A Bemelman
Journal:  Surg Endosc       Date:  2022-05-23       Impact factor: 3.453

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.